BC
AXSM icon

Boxer Capital’s Axsome Therapeutics AXSM Stock Holding History

Boxer Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-400,000
Closed -$35.9M – 7
2024
Q3 		$35.9M Hold
400,000
– – 1.76% 16
2024
Q2 		$32.2M Hold
400,000
– – 1.7% 18
2024
Q1 		$31.9M Hold
400,000
– – 1.58% 19
2023
Q4 		$31.8M Hold
400,000
– – 1.59% 20
2023
Q3 		$28M Hold
400,000
– – 1.49% 26
2023
Q2 		$28.7M Hold
400,000
– – 1.33% 26
2023
Q1 		$24.7M Hold
400,000
– – 1.21% 28
2022
Q4 		$30.9M Buy
+400,000
New +$23.9M 1.63% 20
2020
Q2 		– Sell
-150,000
Closed -$8.82M – 66
2020
Q1 		$8.82M Buy
+150,000
New +$12.2M 0.6% 40

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boxer Capital's AXSM Position: Q4 2024 in Review

Boxer Capital sold out of Axsome Therapeutics (AXSM) in Q4 2024, closing a stake of 400,000 shares — an estimated $35.9M sold.

Boxer Capital first reported a position in AXSM in Q1 2020 and held it in 9 quarters. The position peaked at $35.9M in Q3 2024. 292 funds tracked by Wall St. Rank hold AXSM as of Q4 2024.

  • Boxer Capital reported no remaining Axsome Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 400,000 Axsome Therapeutics shares in Q4 2024, an estimated $35.9M.
  • Boxer Capital first reported a position in Axsome Therapeutics in Q1 2020 and held it in 9 quarters.
  • Boxer Capital's Axsome Therapeutics position peaked at $35.9M in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.